Skip to main content
main-content
Top

11-03-2019 | Non-small-cell lung cancer | News

CheckMate 568 identifies ‘clinically meaningful’ TMB cutoff for advanced NSCLC

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: A tumor mutational burden (TMB) cutoff of 10 mutations/Mb could help identify advanced non-small-cell lung cancer (NSCLC) patients who are most likely to benefit from first-line treatment with nivolumab plus low-dose ipilimumab, report the CheckMate 568 investigators.

In the phase II trial, treatment with nivolumab 3 mg/kg every 2 weeks alongside ipilimumab 1 mg/kg every 6 weeks led to an objective response rate (ORR) of 44% among the 48 patients with a TMB of 10 mutations/Mb or more, while the ORR was 12% for the 50 participants with a lower TMB.

Median progression-free survival (PFS) was similarly improved in the higher versus lower TMB group, at a median of 7.1 and 2.6 months, respectively, and corresponding 6-month rates of 55% and 31%.

Writing in the Journal of Clinical Oncology, Neal Ready (Duke University Medical Center, Durham, North Carolina, USA) and co-investigators point out that a higher TMB was associated with efficacy regardless of PD-L1 expression.

Among patients with a TMB of 10 mutations/Mb, the ORR was 42% for patients with tumoral PD-L1 levels of at least 1% and was 47% for those with PD-L1 levels below 1%. By contrast, the corresponding ORRs were 18% and 5% in participants with a TMB below 10 mutations/Mb.

The researchers therefore summarize that the analysis supports the 10 mutations/Mb threshold “as a clinically meaningful cutoff for response and PFS with this regimen in this patient population.”

They add that the cutoff “was subsequently validated through a preplanned coprimary end point analysis in CheckMate 227,” which showed that PFS was significantly longer with first-line nivolumab plus ipilimumab than chemotherapy in patients with a TMB of 10 or more mutations/Mb, whereas there was no significant difference between the treatments among those with a lower TMB.

The CheckMate 568 trial included 288 patients with treatment-naïve, recurrent stage IIIB or stage IV NSCLC. The assessment of efficacy by TMB was introduced as a secondary endpoint during a protocol amendment and therefore sufficient tissue for TMB analysis – using the FoundationOne CDx platform (Foundation Medicine, Cambridge, Massachusetts, USA) – was available for 120 patients, with a successful result obtained for 98.

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

See also:

share
SHARE
print
PRINT

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.